# Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

> **NCT02390531** · PHASE1 · COMPLETED · sponsor: **Jaeb Center for Health Research** · enrollment: 120 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02390531
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2019-06-04
- **Final completion:** 2021-05-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-11-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02390531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02390531, "Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity". Retrieved via MORVS 2026-10-07 from https://api.morvs.ai/clinical/NCT02390531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*